UGA Analysis Finds Tirzepatide Cuts Over 20% Weight, Beating Semaglutide at 15%
Updated
Updated · University of Georgia · Jun 15
UGA Analysis Finds Tirzepatide Cuts Over 20% Weight, Beating Semaglutide at 15%
3 articles · Updated · University of Georgia · Jun 15
Summary
More than 14,000 non-diabetic patients across 15 Phase 3 trials showed the biggest weight loss with tirzepatide, while semaglutide averaged 15% and liraglutide 8%.
UGA researchers said tirzepatide appears to outperform the others without higher rates of nausea and gastrointestinal side effects, making it the strongest option in their first head-to-head meta-analysis of the three FDA-approved drugs.
Maximum tirzepatide doses of 10 to 15 milligrams produced the largest reductions; liraglutide ranked last and also requires daily injections, versus weekly dosing for tirzepatide and semaglutide.
The review also found a 50 mg oral semaglutide version was still less effective than tirzepatide, though nearly as effective as injectable semaglutide.
The findings land as GLP-1 use expands rapidly in the U.S., with KFF polling showing about 1 in 8 Americans currently take one and 1 in 5 have used one before.
GLP-1 drugs are a breakthrough, but what is the plan to prevent weight regain after stopping?
With dual-hormone drugs proving superior, are 'triple-agonist' obesity treatments the next medical frontier?
Could your DNA predict your success or side effects on new weight-loss drugs like Zepbound?
Tirzepatide vs. Semaglutide: Clinical Superiority, Personalized Response, and the Coming Shift in Obesity Care
Overview
Obesity pharmacotherapy is entering a 'golden age' with major advances in weight management. Tirzepatide has become a new benchmark, showing superior weight loss compared to existing treatments like semaglutide. This is due to its unique dual action, activating both GIP and GLP-1 metabolic receptors. By engaging multiple pathways that regulate weight, tirzepatide achieves a more pronounced and additive effect. These breakthroughs highlight how new mechanisms in obesity drugs can lead to better outcomes, setting higher standards for future treatments.